Arcutis Biotherapeutics, Inc.
ARQT
$20.69
-$0.55-2.59%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 98.17% | 88.47% | 77.33% | 53.07% | 40.34% |
| Total Depreciation and Amortization | -54.21% | 130.42% | 109.95% | 333.57% | 202.11% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.65% | -0.42% | 6.73% | 4.07% | 10.66% |
| Change in Net Operating Assets | 43.81% | -130.96% | -160.04% | 2.97% | -37.06% |
| Cash from Operations | 124.33% | 94.98% | 80.58% | 62.99% | 44.06% |
| Capital Expenditure | 89.61% | -379.72% | -360.40% | -1,084.29% | -117.05% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -176.06% | -202.09% | 157.99% | 239.34% | 58.66% |
| Cash from Investing | -177.00% | -204.97% | 156.86% | 238.48% | 58.20% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 58.18% | -95.80% | -97.78% | -98.19% | -98.16% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 108.03% | -89.47% | -135.82% | -136.16% | -136.19% |
| Foreign Exchange rate Adjustments | 128.48% | 171.49% | -286.57% | 164.15% | -122.54% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 86.39% | -65.43% | -425.21% | 44.03% | -226.40% |